Your browser doesn't support javascript.
Pharmacist responsiveness and readiness for oral antivirals for COVID-19: A rebuttal to the AMA statement regarding the Biden administration's test-to-treat plan.
J Am Pharm Assoc (2003) ; 62(4): 1162-1164, 2022.
Article in English | MEDLINE | ID: covidwho-1768260
ABSTRACT
On March 4, 2022, the American Medical Association (AMA) released a statement in response to the Biden administration's plan of a test-to-treat plan allowing pharmacists to serve as locations to test and provide prescriptions for oral antiviral therapies for the treatment of coronavirus disease 2019 (COVID-19) after a positive test result. The statement by AMA contradicts and underrepresents the impact pharmacists have on clinical practice. Pharmacists have been a crucial part of many efforts including mass vaccination efforts and furnishing of prescriptions for other complex disease states (e.g., pre-exposure prophylaxis and postexposure prophylaxis therapy). Furthermore, health systems have proven that novel approaches to mitigate operational and clinical barriers to COVID-19 therapies may offset the increased demand needed by communities. Herein, this commentary will discuss a viewpoint and counterpoint to the statement put out by AMA, with a focus on pharmacists.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pharmacists / COVID-19 Drug Treatment Type of study: Prognostic study Topics: Vaccines Limits: Humans Country/Region as subject: North America Language: English Journal: J Am Pharm Assoc (2003) Journal subject: Pharmacy Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pharmacists / COVID-19 Drug Treatment Type of study: Prognostic study Topics: Vaccines Limits: Humans Country/Region as subject: North America Language: English Journal: J Am Pharm Assoc (2003) Journal subject: Pharmacy Year: 2022 Document Type: Article